Table 3.
Diagnostic performance of the individual examiners
| Cohort | GS-STAS+ (%) | Examiners | FS-STAS+ (%) | STAS diagnostic performance using frozen sections |
||||
|---|---|---|---|---|---|---|---|---|
| Sensitivity | Specificity | PPV | NPV | Accuracy | ||||
| Total (n = 114) | 43 (38%) | A | 43 (38%) | 67% | 80% | 67% | 80% | 75% |
| B | 39 (34%) | 74% | 90% | 82% | 85% | 84% | ||
| C | 56 (49%) | 81% | 70% | 63% | 86% | 75% | ||
| Primary LC (n = 84) | 31 (37%) | A | 32 (38%) | 71% | 81% | 69% | 83% | 77% |
| B | 32 (38%) | 90% | 93% | 88% | 94% | 92% | ||
| C | 42 (50%) | 87% | 72% | 64% | 91% | 77% | ||
| Metastasis (n = 30) | 12 (40%) | A | 11 (37%) | 58% | 78% | 64% | 74% | 70% |
| B | 9 (30%) | 50% | 83% | 67% | 71% | 70% | ||
| C | 14 (47%) | 67% | 67% | 57% | 75% | 67% | ||
GS-STAS+ is the designation for positive STAS status as determined by the GS analysis using permanent slides in a consensus meeting of 3 pathologists. FS-STAS + reflects STAS detection as determined by the cryo-embedding FS technique. GS, Gold standard; STAS, spread through air spaces; FS, frozen section; PPV, positive predictive value; NPV, negative predictive value; LC, lung cancer.